Reuters logo
BRIEF-Novan presents safety data for SB204 program
2017年4月27日 / 下午1点29分 / 7 个月前

BRIEF-Novan presents safety data for SB204 program

April 27 (Reuters) - Novan Inc

* Novan presents safety data for SB204 program

* Novan inc- in general, all doses of SB204 were well tolerated and not associated with any significant safety issues in these trials

* Novan inc - expects to report additional safety data from long-term safety trial, NI-AC303 in Q3 of this year

* Novan inc- NDA submission targeted in Q1 of 2018 for sb204

* Novan inc- intends to pursue a pre-submission meeting with fda to discuss entirety of SB204 development program in q3 of 2017 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below